BACKGROUND: A high delivery maternal plasma HIV-1 RNA level (viral load [VL]) is a risk factor for mother-to-child transmission and poor maternal health. OBJECTIVE: To identify factors associated with detectable VL at delivery despite initiation of highly active antiretroviral therapy (HAART) during pregnancy. DESIGN: Multicenter observational study. (ClinicalTrial.gov: NCT00028145). SETTING: 67 U.S. AIDS clinical research sites. PATIENTS: Pregnant women with HIV who initiated HAART during pregnancy. MEASUREMENTS: Descriptive summaries and associations among sociodemographic, HIV disease, and treatment characteristics; pregnancy-related risk factors; and detectable VL (>400 copies/mL) at delivery. RESULTS: Between 2002 and 2011, 671 women met inclusion criteria and 13.1% had detectable VL at delivery. Factors associated with detectable VL included multiparity (16.4% vs. 8.0% nulliparity; P = 0.002), black ethnicity (17.6% vs. 6.6% Hispanic and 6.6% white; P < 0.001), 11th grade education or less (17.6% vs. 12.1% had a high school diploma; P = 0.013), initiation of HAART in the third trimester (23.9% vs. 12.3% and 8.6% in the second and trimesters, respectively; P = 0.003), having an HIV diagnosis before the current pregnancy (16.1% vs. 11.0% during the current pregnancy; P = 0.051), and having the first prenatal visit in the third trimester (33.3% vs. 14.3% and 10.5% in the second and third trimesters, respectively; P = 0.002). Women who had treatment interruptions or reported poor medication adherence were more likely to have detectable VL at delivery. LIMITATION: Data on many covariates were incomplete because women entered the study at varying times during pregnancy. CONCLUSION: A total of 13.1% of women who initiated HAART during pregnancy had detectable VL at delivery. The timing of HAART initiation and prenatal care, along with medication adherence during pregnancy, were associated with detectable VL at delivery. Social factors, including ethnicity and education, may help identify women who could benefit from focused efforts to promote early HAART initiation and adherence. PRIMARY FUNDING SOURCE: U.S. Department of Health and Human Services.
BACKGROUND: A high delivery maternal plasma HIV-1 RNA level (viral load [VL]) is a risk factor for mother-to-child transmission and poor maternal health. OBJECTIVE: To identify factors associated with detectable VL at delivery despite initiation of highly active antiretroviral therapy (HAART) during pregnancy. DESIGN: Multicenter observational study. (ClinicalTrial.gov: NCT00028145). SETTING: 67 U.S. AIDS clinical research sites. PATIENTS: Pregnant women with HIV who initiated HAART during pregnancy. MEASUREMENTS: Descriptive summaries and associations among sociodemographic, HIV disease, and treatment characteristics; pregnancy-related risk factors; and detectable VL (>400 copies/mL) at delivery. RESULTS: Between 2002 and 2011, 671 women met inclusion criteria and 13.1% had detectable VL at delivery. Factors associated with detectable VL included multiparity (16.4% vs. 8.0% nulliparity; P = 0.002), black ethnicity (17.6% vs. 6.6% Hispanic and 6.6% white; P < 0.001), 11th grade education or less (17.6% vs. 12.1% had a high school diploma; P = 0.013), initiation of HAART in the third trimester (23.9% vs. 12.3% and 8.6% in the second and trimesters, respectively; P = 0.003), having an HIV diagnosis before the current pregnancy (16.1% vs. 11.0% during the current pregnancy; P = 0.051), and having the first prenatal visit in the third trimester (33.3% vs. 14.3% and 10.5% in the second and third trimesters, respectively; P = 0.002). Women who had treatment interruptions or reported poor medication adherence were more likely to have detectable VL at delivery. LIMITATION: Data on many covariates were incomplete because women entered the study at varying times during pregnancy. CONCLUSION: A total of 13.1% of women who initiated HAART during pregnancy had detectable VL at delivery. The timing of HAART initiation and prenatal care, along with medication adherence during pregnancy, were associated with detectable VL at delivery. Social factors, including ethnicity and education, may help identify women who could benefit from focused efforts to promote early HAART initiation and adherence. PRIMARY FUNDING SOURCE: U.S. Department of Health and Human Services.
Authors: Vlada V Melekhin; Bryan E Shepherd; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Sally S Bebawy; Daniel A Rasbach; Todd Hulgan; Timothy R Sterling Journal: AIDS Patient Care STDS Date: 2010-05 Impact factor: 5.078
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Kunjal Patel; David E Shapiro; Susan B Brogly; Elizabeth G Livingston; Alice M Stek; Arlene D Bardeguez; Ruth E Tuomala Journal: J Infect Dis Date: 2010-04-01 Impact factor: 5.226
Authors: Ingrid T Katz; Roger Shapiro; Daner Li; Usha Govindarajulu; Bruce Thompson; D Heather Watts; Michael D Hughes; Ruth Tuomala Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore Journal: N Engl J Med Date: 2009-04-01 Impact factor: 91.245
Authors: Eliane Borges-Almeida; Helaine M B P M Milanez; Maria Marluce S Vilela; Fernanda G P Cunha; Beatriz M Abramczuk; Suiellen C Reis-Alves; Konradin Metze; Irene Lorand-Metze Journal: BMC Infect Dis Date: 2011-02-03 Impact factor: 3.090
Authors: Lisa Rahangdale; Jordan Cates; JoNell Potter; Martina L Badell; Dominika Seidman; Emilly S Miller; Jenell S Coleman; Gweneth B Lazenby; Judy Levison; William R Short; Sigal Yawetz; Andrea Ciaranello; Elizabeth Livingston; Lunthita Duthely; Bassam H Rimawi; Jean R Anderson; Elizabeth M Stringer Journal: Am J Obstet Gynecol Date: 2016-03 Impact factor: 8.661
Authors: Mary-Margaret Andrews; Deborah S Storm; Carolyn K Burr; Erika Aaron; Mary Jo Hoyt; Anne Statton; Shannon Weber Journal: Public Health Rep Date: 2018-08-10 Impact factor: 2.792
Authors: Kartik K Venkatesh; Leavitt Morrison; Elizabeth G Livingston; Alice Stek; Jennifer S Read; David E Shapiro; Ruth E Tuomala Journal: Obstet Gynecol Date: 2018-05 Impact factor: 7.661
Authors: Kartik K Venkatesh; Leavitt Morrison; Ruth E Tuomala; Alice Stek; Jennifer S Read; David E Shapiro; Elizabeth G Livingston Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079
Authors: Albert M Anderson; Josué Pérez-Santiago; Ziduo Zheng; Eugene Huang; Donald Franklin; Jennifer Iudicello; David J Moore; Ronald J Ellis; Robert K Heaton; Scott L Letendre Journal: AIDS Date: 2019-12-01 Impact factor: 4.632
Authors: Florence M Momplaisir; Kathleen A Brady; Thomas Fekete; Dana R Thompson; Ana Diez Roux; Baligh R Yehia Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240
Authors: Kathleen Squires; Linda-Gail Bekker; Christine Katlama; Yazdan Yazdanpanah; Yan Zhou; Anthony J Rodgers; Mark J DiNubile; Peter A Sklar; Randi Y Leavitt; Hedy Teppler Journal: Open Forum Infect Dis Date: 2017-02-28 Impact factor: 3.835